cardiovascular drugs

11
Cardiovascular Drugs By Devansh Mehta M.PHARM.(PHARMACOLOGY) M.B.A.(Pharmaceutical Marketing and Hospital Administration) B.Pharmacy Contact No.:+91-8171552727

Upload: devansh-mehta

Post on 12-Aug-2015

38 views

Category:

Presentations & Public Speaking


1 download

TRANSCRIPT

Page 1: Cardiovascular drugs

Cardiovascular DrugsBy Devansh Mehta

M.PHARM.(PHARMACOLOGY)M.B.A.(Pharmaceutical Marketing and Hospital Administration)

B.PharmacyContact No.:+91-8171552727

Page 2: Cardiovascular drugs

Pharmacology

• Pharmacology is the Science of Drugs, In broad sense, it deals with the interaction of Exogenously administered chemical molecules with the Living System.

• It encompasses all aspects of knowledge about drugs but most importantly those that are relevant to effective and safe use for medicinal purposes.

Page 3: Cardiovascular drugs

Pharmacodynamics

• Pharmacodynamics: What the drug does to the body. ?????

• This Includes physiological and biochemical effects of drugs and their mechanism of action at mactomolecular / subcellular / organ system levels• E.g. Adrenaline Interaction with adrenoreceptors G-protein mediated

stimulation of cell membrane bound adenylyl cyclase Increased intracellular 3’ 5 ‘ AMP Cardiac stimulation, Hepatic Glycogenolysis and Hyperglycaemia

Page 4: Cardiovascular drugs

Pharmacokinetics

• What the body does to the drug ???

• This refers to movement of the drug in and alteration of the drug by the body; includes absorption, distribution, binding / localization/ storage biotransformation and excretion of the drug• E.g. Digoxin is 70 % absorbed orally, 25 % bound to plasma proteins,

localized in heart, skeletal muscle, liver and kidney, widely distributed a small fraction is metabolized in liver to inactive products and is primarily excreted unchanged by glomerular filteration in kidney has a total body clearance of 150 ml . Min and a plasm half life of 40 hours

Page 5: Cardiovascular drugs

Drug

• It is the single active chemical agent or entity present in a medicine that is used for diagnosis, prevention, treatment and Cure of disease.

• WHO says Drug is any substance or product that is used or Is intended to be used to modify or explore physiological systems or pathological states for the benefit of the recipient.

Page 6: Cardiovascular drugs

Pharmacotherapeutics• It is the application of Pharmacological information together with

knowledge of the disease for its prevention mitigation or cure.

Page 7: Cardiovascular drugs

Clinical Pharmacology

• It is the scientific study of drugs in man. It includes pharmacodynamics and pharmacokinetics investigation in healthy volunteers and in patients, evaluation of efficacy and safety of drugs and comparative trials with other forms of treatment, surveillance of patterns of drug use, adverse effects etc.

Page 8: Cardiovascular drugs

Toxicology

• It is study of poisonous effect of drugs and other chemicals (household, environmental pollutants, industrial, agricultural, homicidal) with emphasis on detection, prevention and treatment of poisonings. It also includes the study of adverse effects of drugs since the same substance can be a drug or poison depending on the dose.

Page 9: Cardiovascular drugs

Drug Nomenclature

• Chemical Name

• Non-proprietary Name

• Proprietary Name

Page 10: Cardiovascular drugs

Essential Drug Concept

• WHO has defined Essential Drugs as “ those that satify the priority healthcare needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety and comparative cost effectiveness. Essential medicine are intended to be available within the context of functioning health systems at all times and in adequate amounts.

Page 11: Cardiovascular drugs

Criteria for selection of Essential Drug

• Adequate data on its efficacy and safety should be available from Clinical studies• It Should be available in a form in which quality, including

bioavailability, and stability on storage can be assured• Its choice should depend upon pattern of prevalent diseases;

availability of facilities and trained personnel financial resources genetic, demographic and environmental factors.

• In case of two or more similar drugs choice should be made on the basis of their relative efficacy, safety, quality, price and availability.